Exemestane
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-EXEMESTANE |
|---|---|
| Type | Drug |
| Aliases | AromasinЕкземестан |
| Status | pending_clinical_signoff |
| Diseases | DIS-BREAST |
| Sources | SRC-ESMO-BREAST-METASTATIC-2024 SRC-NCCN-BREAST-2025 |
Drug Facts
| Class | Aromatase inhibitor (steroidal, irreversible) |
|---|---|
| Mechanism | Steroidal irreversible AI — covalently modifies aromatase active site. Useful as switch therapy after non-steroidal AI failure or in metastatic post-CDK4/6i exposure. |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
Used in BOLERO-2 (exemestane + everolimus post-AI failure), MONARCH-2 (fulvestrant + abemaciclib alternative). Sequential use after anastrozole/letrozole if clinical preference.
Used By
Regimens
REG-EVEROLIMUS-EXEMESTANE- Everolimus + Exemestane (HR+/HER2- breast 3L+, post CDK4/6i and PI3Ki/AKTi)